TB-500 Frag Protocol: How to Cycle It, Timing & What to Expect

Protocol snapshot

• Typical cycle length: 6 to 12 weeks active, followed by a 4 to 8 week off-cycle break; shorter cycles suit acute goals, longer cycles suit chronic tissue remodeling
• Frequency: Twice weekly during loading, stepping down to once weekly or every two weeks during maintenance
• Common delivery routes: Subcutaneous injection (primary); intramuscular used in research models but less common in human protocols
• Key timing notes: Space injections three to four days apart during loading; rotate injection sites and allow each site five to seven days of rest between uses

Who This Protocol Is For

TB-500 Frag is the search term most people land on when looking for information on TB-500 itself. To clear that up before anything else: TB-500 is already a fragment. It replicates the active fragment of Thymosin Beta-4, specifically amino acids 17 through 23 of that naturally occurring protein. The "Frag" in the search term describes what TB-500 is rather than naming a distinct compound. Everything that follows applies to TB-500 as it is commonly sourced and used.

People who look into a TB-500 protocol are almost always coming from one of two places: an acute injury they want to recover from faster, or a stubborn chronic condition that has not responded well to conventional approaches. Tendons, ligaments, muscle tears, joint damage, and connective tissue injuries make up the core of use cases. A smaller but growing group runs TB-500 for general tissue resilience and flexibility, particularly athletes who want to stay ahead of cumulative training wear.

Experience level shapes how the protocol is structured. Someone running their first cycle typically starts at the more conservative end of the loading structure, pays close attention to how the body responds in the first two weeks, and does not stack with other peptides until the baseline is established. More experienced users may pair it with other recovery-focused compounds, though that is a separate decision from running the protocol itself.

Delivery-method preference is a real factor. TB-500 is primarily used in subcutaneous injection form, and the protocol structure in this guide is built around that. People with needle aversion or limited access to injectable forms should discuss alternatives with a qualified provider, since the evidence base for other delivery routes in humans is thin compared to subcutaneous administration.

How Is a TB-500 Frag Cycle Structured?

A TB-500 cycle has a clear two-phase shape that shows up consistently across real-world protocols: a front-loaded loading phase, followed by a lower-frequency maintenance phase, and then an off-cycle break before repeating.

The loading phase runs the first four to six weeks and is where the bulk of the protocol's work happens. Think of it like priming a pump before it can run at steady state. During this window, injections are taken twice weekly, spaced roughly three to four days apart, to build consistent tissue exposure and drive the angiogenic (triggering the formation of new blood vessels) and tissue-repair activity that makes this peptide useful. Skipping or shortening this phase is the single most common mistake users make, and it is why some people report underwhelming results.

The maintenance phase follows the loading window and steps the frequency down significantly. At this point the tissue has received consistent signaling, and the goal shifts from establishing effect to sustaining it. Cycle lengths vary depending on whether the goal is acute recovery or longer-term chronic tissue remodeling. Shorter cycles of six to eight weeks are common for acute injuries; protocols targeting chronic conditions tend to run ten to twelve weeks. After the active cycle ends, an off-cycle break follows before the protocol restarts. Full phase detail and off-cycle structure are covered in the dedicated sections below.

How Your Dose Is Determined

What moves a TB-500 dose:

• Your goal: The most meaningful variable. Acute injuries, where rapid tissue repair is the priority, are associated with the higher end of the range and the more aggressive loading structure. Chronic conditions, where the goal is sustained tissue remodeling, sit toward the lower end and use a more measured loading structure. Maintenance and general resilience goals trend lower still, with reduced frequency as the defining feature.
• Experience level: First-cycle users typically start conservatively and assess response before committing to a full loading structure. Users who have run TB-500 before have more confidence adjusting within the range based on how their body has responded previously.
• Delivery route: Subcutaneous injection is the primary route for human protocols, and dose conventions are built around it. Intramuscular administration appears in rodent research models but is not the standard reference point for real-world human use.
• Individual response: Two people with identical goals and experience can land in different places based on how their tissue responds, how quickly inflammation signals change, and whether side effects emerge. Early cycles are partly observational.

One practical note worth stating clearly: TB-500 is dosed in milligrams, not micrograms. Users accustomed to other peptides sometimes apply the wrong unit convention and end up with a fraction of the intended amount. The per-injection amount is meaningfully larger than most other peptides in this space, and the unit distinction is not trivial.

There is no single dose that fits everyone running a TB-500 Frag protocol. The goal type, the injury context, and the individual's response all shape where within the range a given person lands, which is exactly what the app is built to personalize.

Your dose should not be a guess. The MyPeptidePal Protocol Creator takes your goal type (acute recovery versus chronic remodeling versus general maintenance), your delivery route, and your phase structure (loading versus maintenance frequency) and builds your TB-500 Frag protocol: your dose, your cycle, and your timing.

Get your protocol at mypeptidepal.ai

How Often Do You Take TB-500 Frag?

Frequency is one of the defining structural features of a TB-500 protocol, and it changes across the cycle in a deliberate way.

During the loading phase, twice weekly is the most consistently referenced pattern. The reasoning is tied to the compound's short half-life. TB-500's active fragment clears the system relatively quickly, so spacing injections three to four days apart keeps tissue exposure consistent throughout the week. Rather than creating a spike-and-drop pattern, this approach sustains the signaling needed to drive angiogenic activity across the full loading window.

Once the loading phase ends and the maintenance phase begins, frequency steps down to once weekly or every two weeks for lower-intensity maintenance goals. The per-injection amount stays consistent while the number of injections per week changes, which is a distinction that matters for planning supply and reading protocols accurately.

Timing relative to other activities is a secondary consideration. For athletes, post-workout administration is commonly mentioned. For acute injuries, starting the protocol as early as possible, ideally within the first week of injury, is consistently cited as beneficial. Injection site rotation matters more with TB-500 than with most other peptides because injection volumes per administration are larger. Each site benefits from a five to seven day rest period before reuse. The four primary rotation sites are the abdomen, outer thigh, upper arm, and gluteal area. The systemic healing reach of the compound is not affected by which site is used.

Loading and Maintenance Phases

The two-phase structure is the standard, and understanding what each phase is actually doing explains why collapsing them into a single steady-dose approach produces weaker results.

The loading phase is about reaching what some protocols describe as the angiogenic threshold: the point at which tissue exposure is sufficient to drive meaningful new blood vessel formation and initiate the repair cascade. Twice-weekly injections over four to six weeks build and sustain that level of tissue activity. What makes the loading phase distinct is the total weekly exposure from injecting twice rather than once. Cutting it short, or under-doing the frequency, is the equivalent of priming a pump halfway and then wondering why the pressure is low.

One clarification that trips up many users: the per-injection dose during loading and the per-injection dose during maintenance are typically the same in standard TB-500 protocols. The step-down between phases is in weekly frequency, not in the amount per injection. This is different from some other peptide protocols where loading genuinely uses a higher per-injection amount.

Acute injury goals typically run the full four to six week loading window. Chronic conditions may extend the active loading period toward six to eight weeks before stepping down, which is why overall cycle lengths for those goals often reach ten to twelve weeks. The maintenance phase that follows is not a continuation of loading at reduced intensity. Its purpose shifts: sustaining the tissue environment created during loading while structural repair continues. The protocol stays in this phase until the active cycle ends and the off-cycle break begins.

Off-Cycle Considerations

Off-cycle breaks are a standard part of TB-500 protocol design. Continuous, uninterrupted long-term use is not the norm, and the reasoning behind the convention is worth understanding.

The primary rationale for cycling on and off is precautionary. TB-500's long-term safety profile in humans is not fully characterized, and the conservative approach across protocols reflects that. A break gives the body a rest from consistent angiogenic signaling and allows for reassessment before the next cycle. It also gives the user a cleaner read on progress: if recovery has advanced meaningfully, the off-cycle period reveals that; if the condition is returning, it signals that a second cycle is warranted.

Off-cycle break lengths typically fall in the four to eight week range. Shorter active cycles of six to eight weeks commonly pair with a four week break. Longer active cycles of ten to twelve weeks pair with breaks of six to eight weeks, sometimes extending to two months in structured multi-cycle plans. Some multi-cycle approaches describe roughly three active cycles per year when accounting for both cycle and break durations.

An important point on what happens during the off-cycle: the tissue repair that TB-500 initiates does not stop when dosing ends. The angiogenic signaling has been established, and structural repair continues as a biological process. Pain relief often appears well before tissue repair is complete, which means users who stop dosing early because they feel better risk ending the protocol before structural recovery is finished. Completing the full intended cycle, including the maintenance phase, before entering the off-cycle break is the better approach.

What to Expect Week by Week

• Week 1 to 2: Early changes are typically subtle. The most commonly reported first sign is mild reduction in acute inflammation and some easing of pain at the injury site. Some users describe feeling less stiff or noticing a slight improvement in range of motion. These are early signals, not full effects, and they appear inconsistently in the first two weeks.
• Week 3 to 4: The cumulative picture becomes more apparent. Meaningful pain reduction and noticeable improvements in mobility are more consistently reported in this window. Tissue resilience, the sense that the affected area is handling stress differently, begins to emerge.
• Week 5 to 8: The range where more substantial tissue regeneration is commonly reported. Reduced scarring, improved functional recovery, and sustained mobility gains appear in this window across protocol logs. Users running TB-500 for acute injuries often reach meaningful functional recovery during this period.
• Beyond 8 weeks: Relevant for protocols targeting chronic conditions or long-term structural remodeling. Continued improvement and reduction in chronic pain are reported by users running longer cycles. The repair process remains active even as week-to-week changes become less dramatic.

These are commonly reported ranges drawn from real-world protocols and user logs, not guarantees. Individual results vary based on injury type, delivery route, consistency of dosing, and severity of the underlying condition. That said, users who run a well-structured loading phase consistently for an acute tendon or connective tissue injury commonly describe a recognizable arc: meaningful pain reduction by weeks three to four, functional recovery in the five to eight week range, and continued structural improvement carrying through the maintenance phase. That trajectory, when it appears, is what a well-run TB-500 cycle tends to look like.

Common Protocol Mistakes

Skipping or cutting short the loading phase. This is the single most consequential mistake in a TB-500 protocol. The loading phase exists to reach the level of tissue exposure needed for meaningful angiogenic activity. Users who jump straight to maintenance-equivalent frequency, or who cut loading short because they feel better, report disappointing results consistently. Completing the full loading window is more important than any other single protocol decision.

Stopping when pain eases. Pain relief from TB-500 consistently precedes structural tissue repair. Feeling better by week three or four does not mean the tissue has healed. Users who stop dosing when pain resolves risk leaving structurally compromised tissue that re-injures more easily. Completing the full intended cycle, including the maintenance phase, is the better approach.

Dosing in micrograms instead of milligrams. TB-500 is dosed in milligrams. Users who come from other peptides where microgram-level dosing is standard sometimes apply that convention and end up with a fraction of the intended dose. The practical effect of this error is dramatic underdosing with no therapeutic benefit.

Mixing TB-500 and BPC-157 in the same vial. These two peptides are commonly stacked, but combining them in a single vial causes instability and degrades both compounds. They can be administered in the same session but must remain in separate vials and solutions. Using the same reconstituted vial for both wastes both peptides.

Poor injection site management. Because TB-500 injection volumes per administration are larger than most other peptides, site rotation matters more than usual. Returning to the same site before it has had five to seven days of rest creates local irritation and, over a multi-week loading phase, can cause cumulative tissue stress at frequently used sites. Tracking rotation across the four primary sites systematically prevents this.

Sourcing from unverifiable suppliers. The absence of regulated supply chains means product quality varies significantly. Contamination risks including endotoxins, missequenced peptide chains, and microbial agents are elevated in products from unverified sources. Seeking products from facilities that provide independent certificates of analysis and meet established compounding standards reduces but does not eliminate this risk.

TB-500 is not FDA-approved for human use and is classified as a Category 2 bulk drug substance, meaning it is not permitted for pharmaceutical compounding under current FDA guidance. Tested athletes should also be aware that TB-500 is listed on the World Anti-Doping Agency Prohibited List under peptide hormones and related substances.

Frequently Asked Questions

How long is a typical TB-500 Frag cycle?

Most TB-500 protocols run six to twelve weeks of active dosing, depending on the goal. Acute injury recovery often fits in the six to eight week range, while chronic conditions and long-term tissue remodeling goals are more commonly associated with ten to twelve week cycles. The MyPeptidePal Protocol Creator uses your specific goal and situation to set the cycle length that fits.

How often do you take TB-500 Frag?

During the loading phase, twice weekly is the most consistently referenced frequency, with injections spaced three to four days apart. Once the loading phase ends, most protocols step down to once weekly or every two weeks for the maintenance period. The twice-weekly loading frequency is tied to the compound's short half-life and the need to maintain consistent tissue exposure throughout the week.

Does TB-500 Frag need a loading phase?

Yes, and this is one of the most important structural features of the protocol. The loading phase drives tissue levels to the point where meaningful angiogenic activity can occur. Skipping it and starting at a lower frequency from the beginning is consistently associated with weaker results.

Do you need to cycle off TB-500 Frag?

Yes. Off-cycle breaks are standard across TB-500 protocols and typically fall in the four to eight week range, scaled to the length of the active cycle. The cycling convention reflects a precautionary approach, and continuous long-term use is not the norm.

What is the difference between TB-500 and TB-500 Frag?

There is no meaningful difference in the context of protocols. TB-500 itself is already a synthetic fragment, specifically the active fragment of Thymosin Beta-4 covering amino acids 17 through 23. When people search for TB-500 Frag, they are referring to TB-500. The term Frag describes what the compound is, not a separate or modified version of it.

Can TB-500 be injected near the injury site?

Some protocols suggest injecting subcutaneously near the affected tissue for localized conditions, though TB-500 works systemically regardless of where the subcutaneous injection is placed. Standard rotation across the abdomen, outer thigh, upper arm, and gluteal area is the approach for most users, and the healing reach of the compound is not meaningfully limited by injection site selection.

Disclaimer

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world protocols for TB-500 Frag in one place.